The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

##STR00001##

A process is provided for making a WEE1 inhibitor of the formula (1A) useful in the treatment of conditions characterized by excessive cellular proliferation, such as cancer. In some embodiments, processes are provided for making intermediate compounds of the formulae (3), (5) and (6) as defined herein.

A process is provided for making a WEE1 inhibitor of the formula (1A) useful in the treatment of conditions characterized by excessive cellular proliferation, such as cancer. In some embodiments, processes are provided for making intermediate compounds of the formulae (3), (5) and (6) as defined herein.

Disclosed herein are methods for preparing tertiary alcohols from an optionally substituted phenyl ketone or an optionally substituted pyridinyl ketone that includes the use of a chiral ligand and boron trifluoride diethyl etherate. Tertiary alcohols can be used to prepare synthetic versions of natural products and/or pharmaceuticals.

The present invention includes in one aspect substituted 2-oxo-1,2,5,6-tetrahydrobenzo[h]quinoline-3-carboxylic acids, analogues thereof, and compositions comprising the same, which can be used to treat and/or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) in a patient. In certain embodiments, the invention provides a compound of formula (I), or a salt, solvate, geometric isomer, stereoisomer, tautomer, and any mixtures thereof: ##STR00001##

The present invention includes in one aspect substituted 2-oxo-1,2,5,6-tetrahydrobenzo[h]quinoline-3-carboxylic acids, analogues thereof, and compositions comprising the same, which can be used to treat and/or prevent hepatitis B virus (HBV) infection and/or hepatitis D virus (HDV) in a patient. In certain embodiments, the invention provides a compound of formula (I), or a salt, solvate, geometric isomer, stereoisomer, tautomer, and any mixtures thereof: ##STR00001##

Disclosed are a bicyclic compound used as a non-steroidal selective androgen receptor modulator and the use thereof in the preparation of a drug for treating related diseases which are mediated by an androgen receptor. Specifically, the present invention discloses a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof.

##STR00001##

Disclosed are a bicyclic compound used as a non-steroidal selective androgen receptor modulator and the use thereof in the preparation of a drug for treating related diseases which are mediated by an androgen receptor. Specifically, the present invention discloses a compound as shown in formula (I) or a pharmaceutically acceptable salt thereof.

##STR00001##

Mitochondrial targeting compounds for the treatment of cancer and other disorders associated with mitochondrial function, including diabetes, autoimmune diseases, inflammatory diseases, cardiovascular diseases and neurodegenerative diseases and their preparation. The present invention is also directed to the pharmaceutical compositions and treatment methods, prodrugs based on those compounds and the use thereof.

The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof are bicyclic compounds that are inhibitors of PD-1/PD-L1 interaction/activation. ##STR00001##